Splitting high-dose oral methotrexate improves bioavailability: A pharmacokinetic study in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 3, 2006, Pages 481-485

  Hoekstra, Monique ^a,c   Haagsma, Cees ^b   Neef, Cees ^c   Proost, Johannes ^d   Knuif, Antonius ^c   Van De Laar, Mart ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b Ziekenhuigroep Twente ^*  (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d University Centre for Pharmacy   (Netherlands)

Author keywords

Methotrexate; Pharmacokinetics; Rheumatoid Arthritis; Split dose

Indexed keywords

AUROTHIOMALATE; CHLOROQUINE; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 33644681620     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ballis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342-5.
2. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987;110:788-92.
3. Balis FM, Mirro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-6.
4. Hoekstra M, Haagsma CJ, Neef C, Proost HJ, Knuif T, van de Laar MAFJ. Bioavailability of high dose methotrexate: oral versus subcutaneous administration. J Rheumatol 2004;31:645-8.
5. Abbott Laboratories Diagnostics Division. TDX system assays manual. North Chicago, IL: Abbott Laboratories; 1984.
6. Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
7. Akaike H. An information criterion. Math Sci 1976;14:5-9.
8. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.
9. Seideman P. Methotrexate - the relationship between dose and clinical effect. Br J Rheumatol 1993;32:751-3.
10. Alsufyani K, Ortiz-Alvarez O, Cabrai DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004;31:179-82.
11. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of patenterai methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate. Arthritis Rheum 2004;50:364-71.
12. Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. J Rheumatol 1995;22:630-2.
13. Oguey D, Kölliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611-4.
14. Carpentier N, Bertin P, Marquet P, et al. Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis? J Rheumatol 1998;25:1270-5.
15. Steele WH, Stuart JFB, Lawrence JR, et al. Enhancement of methotrexate absorption by subdivision of dose. Cancer Chemother Pharmacol 1979;3:235-7.